1-Bromo-4-iodonaphthalene | CAS:63279-58-3

We serve 1-Bromo-4-iodonaphthalene CAS:63279-58-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromo-4-iodonaphthalene

Chemical Name:1-Bromo-4-iodonaphthalene
CAS.NO:63279-58-3
Synonyms:1-Iodo-4-bromoaphthalene
1-Brom-4-jodnaphtaln
1-Brom-4-jod-naphthalin
Naphthalene,1-bromo-4-iodo
1-bromo-4-iodo-naphthalene
Molecular Formula:C10H6BrI
Molecular Weight:332.96300
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 1-Bromo-4-iodonaphthalene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-bromo-4-iodo-naphthalene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Naphthalene,1-bromo-4-iodo Use and application,Naphthalene,1-bromo-4-iodo technical grade,usp/ep/jp grade.


Related News: Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.9-Bromo-10-(2-naphthyl)anthracene manufacturer In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.2-Methoxy-3-isobutyl pyrazine supplier Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.Methyl [(dimethoxyphosphoryl)sulfanyl]acetate vendor Others wondered if this was a concerted effort to promote certain herbal products to boost their makers’ share prices ahead of the Chinese stock market’s re-opening Monday.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.